First test of new cancer pill targets advanced tumors

NCT ID NCT06846099

Summary

This first-in-human study tested a new oral drug called RP903 in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study focused on specific cancers, including ovarian, breast, cervical, and endometrial cancers, especially those with a certain genetic change (PIK3CA mutation).

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Cancer Hospital of Fudan University

    Shanghai, China

  • Affiliated Hospital of Jining Medical College

    Jining, China

  • Beijing Cancer Hospital

    Beijing, China

  • Ceneral Hosipital of Ningxia Medical University

    Yinchuan, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Guangxi Medical University Cancer Hospital

    Nanning, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Jilin Cancer Hospital

    Changchun, China

  • Jilin University First Hospital

    Changchun, China

  • Liaoning Cancer Hospital&Institute

    Shenyang, China

  • Linyi Cancer Hospital

    Linyi, China

  • Shandong Cancer Hospital & Institute

    Jinan, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Sir Run Run Shaw Hospital

    Hangzhou, China

  • Suining Central Hospital

    Suining, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.